Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06910969 · ClinicalTrials.gov registry record · NA

Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

A NA study of Graft-Versus-Host Disease and Bone Marrow Transplant Complications, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
350
Enrollment target
2
Study locations

NCT06910969: Recruiting NA study of Graft-Versus-Host Disease and Bone Marrow Transplant Complications, sponsored by Massachusetts General Hospital.

NCT06910969 is a NA study of Graft-Versus-Host Disease and Bone Marrow Transplant Complications that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 350 participants, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (379% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06910969, a NA study of Graft-Versus-Host Disease and Bone Marrow Transplant Complications, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
350 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.

Primary Outcome

Compare patient QOL as measured by the FACT-BMT between the two study groups. The FACT-BMT ranges from 0-164 with higher scores indicating better QOL

Interventions

  • BEHAVIORAL HORIZONS Intervention
  • BEHAVIORAL Minimally enhanced usual care

Study Locations (2)

Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2025-08-13
Est. Completion 2030-02-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06910969 shows while recruiting

NCT06910969 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (379% higher).

The record links to 2 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 2 interventions - of which HORIZONS Intervention is the first listed.

NCT06910969 reports a single indexed study location in Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06910969 about?

NCT06910969 is a clinical study titled "Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease". The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-ve...

What is the current status of trial NCT06910969?

This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2025-08-13. Estimated completion is 2030-02-01.

What conditions does trial NCT06910969 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, Bone Marrow Transplant Complications.

What interventions are being tested in trial NCT06910969?

The interventions under investigation include: HORIZONS Intervention (BEHAVIORAL), Minimally enhanced usual care (BEHAVIORAL).

Who is sponsoring clinical trial NCT06910969?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06910969 being conducted?

This trial has 2 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06910969's enrollment target sits among peer trials

350 4th of 38 higher than 35 of 38 other Graft-Versus-Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06910969, the US trial registry maintained by the National Library of Medicine. NCT06910969 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.